Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gö6976 is a potent, cell-permeable, and selective small molecule inhibitor of conventional protein kinase C (cPKC) isoforms, including PKCα, PKCβ, and PKCγ, with IC50 values in the low nanomolar range. It belongs to the indolocarbazole chemical class and acts by competing with ATP for the kinase domain binding site. Unlike non-selective inhibitors like staurosporine, Gö6976 does not inhibit novel (nPKC) or atypical (aPKC) isoforms at concentrations that effectively block cPKCs. Additionally, it is a highly potent inhibitor of Protein Kinase D (PKD) and has demonstrated inhibitory activity against Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Primarily utilized as a biochemical research tool, Gö6976 is used to investigate PKC-mediated pathways in cell differentiation, apoptosis, and oncogenesis, particularly in studies involving endometrial cancer and various leukemias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gö6976.